Literature DB >> 8613674

Mapping of the dominant neutralizing antigenic site of a virus using infected cells.

H P Roost1, A Haag, C Burkhart, R M Zinkernagel, H Hengartner.   

Abstract

Panels of neutralizing monoclonal antibodies (MAbs) and antisera to vesicular stomatitis virus of the serotype Indiana (VSV-IND) were generated in mice and rats. They were used in competition studies to map epitopes on the viral glycoprotein that are involved in virus neutralization. Since neutralizing antibodies bind to the viral glycoproteins on the surface of intact viruses and of infected cells, infected cells were used for measuring the binding of competing antibodies by cytofluorometric analysis. A single immunodominant neutralizing epitope was recognised by 90% (58) of the MAbs including all of strong neutralizing capacity. 10% (6) of the neutralizing MAbs that all exhibited low neutralizing titers recognised spatially closely related epitopes. This approach offers a convenient method to determine antibody interaction with complex conformational epitopes of membrane proteins.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8613674     DOI: 10.1016/0022-1759(95)00252-9

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  4 in total

1.  Moving the glycoprotein gene of vesicular stomatitis virus to promoter-proximal positions accelerates and enhances the protective immune response.

Authors:  E B Flanagan; L A Ball; G W Wertz
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

2.  Virus neutralization by germ-line vs. hypermutated antibodies.

Authors:  U Kalinke; A Oxenius; C Lopez-Macias; R M Zinkernagel; H Hengartner
Journal:  Proc Natl Acad Sci U S A       Date:  2000-08-29       Impact factor: 11.205

3.  Secondary rearrangements and hypermutation generate sufficient B cell diversity to mount protective antiviral immunoglobulin responses.

Authors:  C López-Macías; U Kalinke; M Cascalho; M Wabl; H Hengartner; R M Zinkernagel; A Lamarre
Journal:  J Exp Med       Date:  1999-06-07       Impact factor: 14.307

Review 4.  Neutralizing antiviral antibody responses.

Authors:  R M Zinkernagel; A LaMarre; A Ciurea; L Hunziker; A F Ochsenbein; K D McCoy; T Fehr; M F Bachmann; U Kalinke; H Hengartner
Journal:  Adv Immunol       Date:  2001       Impact factor: 3.543

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.